Business Description
Neovacs SA
NAICS : 325412
SIC : 2834
ISIN : FR001400MV37
Compare
Compare
Traded in other countries / regions
ALNEV.France0LWA.Germany0W8U.UK IPO Date
2011-05-24Description
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.36 | |||||
| Equity-to-Asset | 0.93 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.21 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | -3.08 | |||||
| Beneish M-Score | -2469.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EPS without NRI Growth Rate | 96.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 22.77 | |||||
| 9-Day RSI | 25.6 | |||||
| 14-Day RSI | 25.7 | |||||
| 6-1 Month Momentum % | -87.67 | |||||
| 12-1 Month Momentum % | -100 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.25 | |||||
| Quick Ratio | 1.25 | |||||
| Cash Ratio | 0.29 | |||||
| Days Sales Outstanding | 161.08 | |||||
| Days Payable | 1621.26 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -7105.36 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 5.62 | |||||
| Operating Margin % | -2306.18 | |||||
| Net Margin % | -1637.27 | |||||
| FCF Margin % | -396.44 | |||||
| ROE % | -17.69 | |||||
| ROA % | -15.91 | |||||
| ROIC % | -23.21 | |||||
| ROC (Joel Greenblatt) % | -1928.06 | |||||
| ROCE % | -18.82 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | 0.02 | |||||
| EV-to-EBITDA | 0.05 | |||||
| EV-to-Revenue | -0.3 | |||||
| EV-to-FCF | 0.07 | |||||
| Price-to-Net-Current-Asset-Value | 0.5 | |||||
| Earnings Yield (Greenblatt) % | 4872.61 | |||||
| FCF Yield % | -2679.75 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neovacs SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.534 | ||
| EPS (TTM) (€) | -30825.983 | ||
| Beta | 0 | ||
| Volatility % | 108.76 | ||
| 14-Day RSI | 25.7 | ||
| 14-Day ATR (€) | 0.050587 | ||
| 20-Day SMA (€) | 0.24738 | ||
| 12-1 Month Momentum % | -100 | ||
| 52-Week Range (€) | 0.16 - 24000 | ||
| Shares Outstanding (Mil) | 0.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neovacs SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neovacs SA Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Neovacs SA Frequently Asked Questions
What is Neovacs SA(XPAR:ALNEV)'s stock price today?
The current price of XPAR:ALNEV is €0.17. The 52 week high of XPAR:ALNEV is €24000.00 and 52 week low is €0.16.
When is next earnings date of Neovacs SA(XPAR:ALNEV)?
The next earnings date of Neovacs SA(XPAR:ALNEV) is .
Does Neovacs SA(XPAR:ALNEV) pay dividends? If so, how much?
Neovacs SA(XPAR:ALNEV) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers